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Abstract: Regular blood transfusions as supportive care for patients with chronic anemia 
inevitably lead to iron overload as humans cannot actively remove excess iron. The cumulative 
effects of iron overload cause significant morbidity and mortality if not effectively treated with 
chelation therapy. Based on a comprehensive clinical development program, the once-daily, 
oral iron chelator deferasirox (Exjade®) is approved for the treatment of transfusional iron 
overload in adult and pediatric patients with various transfusion-dependent anemias, including 
β-thalassemia and the myelodysplastic syndromes. Deferasirox dose should be titrated for each 
individual patient based on transfusional iron intake, current iron burden and whether the goal 
is to decrease or maintain body iron levels. Doses of 30 mg/kg/day have been shown to be 
effective with a safety profile consistent with that observed at doses 30 mg/kg/day. Recent 
data have highlighted the ability of deferasirox to decrease cardiac iron levels and to prevent 
the accumulation of iron in the heart. The long-term efficacy and safety of deferasirox for up to 
5 years of treatment have now been established. The availability of this effective and generally 
well tolerated oral therapy represents a significant advance in the management of transfusional 
iron overload.
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Iron overload and chelation therapy
The human body has many mechanisms to absorb, transfer and store essential dietary 
iron, but none to excrete excess amounts. It is therefore inevitable that patients who 
undergo regular transfusion therapy to treat chronic anemia, such as those with 
β-thalassemia and the myelodysplastic syndromes (MDS), will develop iron overload, 
since every unit of blood contains approximately 200 mg of iron.1 Iron overload from 
transfusions may be exacerbated in some patients due to increased absorption of iron 
from the diet in response to ineffective erythropoiesis.2 Excess iron is deposited in 
parenchymal tissue, including the liver, heart and endocrine system, which leads to 
ongoing damage and, ultimately, to organ failure.
Iron chelation therapy is the only viable option for the treatment of transfusional 
iron overload and can prevent further cellular iron uptake and reduce levels of morbidity 
and mortality in regularly transfused patients.3–5 Deferoxamine (DFO; Desferal®) is the 
current standard of care for iron chelation therapy; however, as DFO is a large molecule 
with a short half-life (20 to 30 minutes), treatment requires a demanding regimen of 
slow continuous infusion over 8 to 12 hours, 5 to 7 days/week, which often results in 
poor compliance.6 The 3-times daily chelator deferiprone (Ferriprox®) was the first oral 
chelator to reach market and it is currently available in a number of countries outside Therapeutics and Clinical Risk Management 2009:5 858
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the USA and Canada for the second-line treatment of iron 
overload in adult patients with thalassemia major for whom 
DFO therapy is contraindicated or inadequate.7 The use of 
deferiprone has partly been restricted due to the occurrence 
of serious adverse events such as arthropathy (common), 
neutropenia and agranulocytosis (rare).8,9
Deferasirox (Exjade®), which became available in 
2005, is an oral iron chelator that requires once-daily 
administration. It is currently approved in more than 
90 countries for the treatment of chronic iron overload 
due to blood transfusions in pediatric and adult patients.10 
Deferasirox has been evaluated in patients with a wide range 
of underlying anemias and a wealth of clinical data is now 
available. This review will provide an update on the use 
of deferasirox, primarily focusing on the recent long-term 
efficacy and safety data available from the extension studies, 
new analyses in patients with MDS, aplastic anemia (AA) 
and Diamond-Blackfan anemia (DBA), as well as updates 
on the effects of deferasirox on cardiac iron levels.
Pharmacodynamics 
and pharmacokinetics of deferasirox
Chemistry and pharmacodynamic 
properties
Deferasirox represents a new class of tridentate iron 
chelators, the N-substituted bis-hydroxyphenyl-triazoles.11 
As a tridentate iron chelator, two molecules are required 
to form a stable complex with each iron (Fe3+) atom; the 
active molecule in deferasirox (ICL670) is highly lipophilic 
and 99% protein bound. Deferasirox has a high affinity and 
selectivity for Fe3+, which is approximately 14 and 21 orders 
of magnitude greater than its affinity for copper or zinc, 
respectively, which minimizes the potential for depletion of 
these trace elements.12 Animal models in several species, such 
as rats, gerbils and marmosets, demonstrated that deferasirox 
could efficiently and selectively mobilize iron from various 
tissues such as hepatocytes and cardiomyocytes, and could 
also promote iron excretion.11,13,14 Deferasirox is primarily 
metabolized by glucuronidation, with subsequent biliary 
excretion, and the deferasirox–iron complex is excreted in 
the feces.15
Pharmacokinetic properties
Deferasirox is rapidly absorbed with a median tmax of 
1 to 2 hours and a mean elimination half-life of 7 to 
16 hours.16 The plasma concentration of deferasirox is 
proportional to the administered dose17,18 and plasma levels 
are maintained within the therapeutic range over 24 hours 
following once-daily administration.16 Cmax, area-under-curve 
and half-life are similar in children (aged  12 years) and 
adolescents (aged  12 years). Exposure to deferasirox is 
approximately 20% to 30% lower in children and adolescents 
than in adults,17 and is significantly lower in pediatric patients 
aged 6 years compared with older pediatric patients. These 
factors may add an additional margin for tolerability and 
mean that pediatric patients require higher deferasirox doses 
than adults to achieve comparable efficacy. As the bioavail-
ability of deferasirox is affected by food when consumed 
concomitantly, it is recommended that it is administered at 
least 30 minutes before eating.19
Efficacy of deferasirox
introduction to deferasirox clinical trials
The clinical efficacy of deferasirox has been thoroughly 
evaluated in patients with a wide range of transfusion-dependent 
anemias, including β-thalassemia, MDS, sickle cell disease 
(SCD), AA, DBA and other rare anemias. Five pivotal 1-year 
core studies were conducted in more than 1000 patients,16,20–23 
while more than 900 patients were enrolled into subsequent 
extension studies and will receive treatment with deferasirox 
for up to a further 4 years. A wealth of data are also now 
available from a global program of additional studies, the 
largest of which include ESCALATOR (237 patients with 
β-thalassemia)24,25 and EPIC (1744 patients with various 
underlying anemias)26 (Table 1).
Factors impacting on deferasirox efficacy
The pivotal 1-year clinical studies demonstrated that the effi-
cacy of deferasirox is dependent on both dose and ongoing 
transfusional iron intake.16,20–23,27 Although doses of 5 and 
10 mg/kg/day are able to effectively remove iron they are 
generally insufficient to balance the iron uptake from regular 
blood transfusions. Doses of 20 to 30 mg/kg/day are able 
to maintain or reduce body iron burden depending on iron 
intake.
For most patients the recommended starting dose for 
deferasirox is 20 mg/kg/day,18 however this dose can be 
modified based on iron intake, current iron burden and 
a patient’s individual therapeutic goal (ie, whether the 
aim is to decrease or maintain body iron levels);10 local 
prescribing information should be consulted. If necessary, 
deferasirox dose adjustments should be made in steps of 
5 to 10 mg/kg/day every 3 to 6 months based on serum ferritin 
trends. Data from the ESCALATOR study suggested that 
a starting dose of 20 mg/kg/day is insufficient to decrease Therapeutics and Clinical Risk Management 2009:5 859
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iron burden in heavily iron-overloaded patients, since dose 
increases above 20 mg/kg/day were required in 185/237 
patients (78%) in the initial 1-year treatment period.24 Further 
dose increases were performed in 137/233 patients (59%) 
in the extension study, with increases to 30 mg/kg/day 
necessary in 112 patients; significant improvements in liver 
iron concentration (LIC) and serum ferritin were observed 
following these dose increases (Figure 1).25 The importance 
of timely and appropriate deferasirox dose adjustments 
to enable patients to achieve target serum ferritin levels 
has also been highlighted in the extension phases of the 
pivotal studies. Patients who initially received deferasirox 
5/10 mg/kg/day had increases in serum ferritin during the 
core 1-year treatment period, however a gradual decline in 
iron burden to below baseline levels was observed once doses 
were subsequently increased.28,29 Figure 2 shows that doses 
of 20 mg/kg/day were necessary before patients were able 
to achieve a significant reduction in serum ferritin.28
The dosing approach used in the EPIC study accounted 
for iron intake as patients received initial deferasirox doses 
of 10 to 30 mg/kg/day depending on transfusion history, 
followed by dose titration in steps of 5 to 10 mg/kg/day 
every 3 months according to serum ferritin trends and 
safety markers.26,27 Changes in serum ferritin over the 
1-year treatment period were reflective of dosage adjust-
ments and mean iron intake (Figure 3).26 Significant 
decreases in serum ferritin were observed in each overall 
disease cohort (Table 2).30–34 These data from the EPIC study 
show that it is important to regularly monitor transfusional 
iron intake and serum ferritin levels during deferasirox 
therapy in order to optimize dosing.
Some patients will require escalation to 30 mg/kg/day 
to achieve therapeutic goals. A retrospective analysis of 
228 patients who received deferasirox doses of 30 mg/kg/day 
in the extension studies and ESCALATOR demonstrated a 
significant reduction in median serum ferritin of 370 ng/mL 
(P  0.001) from pre-dose-escalation to the time-of-analysis.35 
These findings have important implications for patients who 
are heavily transfused and may require higher doses of 
deferasirox to reduce body iron burden.
Efficacy across different  
underlying anemias
β-thalassemia major
As complications of iron overload have been most widely 
studied in β-thalassemia major, this population was the 
primary focus of the deferasirox clinical trial program. 
The efficacy of deferasirox in this population was clearly 
demonstrated in the pivotal 1-year Phase III study 
(n = 296), where doses of 20 or 30 mg/kg/day provided 
dose-dependent changes in LIC and serum ferritin.20 These 
data were confirmed in several trials including EPIC, where 
Table 1 Trial design and key efficacy results from the ESCALATOR and EPIC studies
Design Population Treatment Key results
eSCALATOR: 
Open-label, 1 year24 
 
Subsequent extension 
study of at least 1 
additional year25
Pediatric (2 years) and adult 
patients with β-thalassemia, n = 237 
(n = 233 in extension study)  
All patients were previously 
unsuccessfully chelated with DFO 
and/or deferiprone
Deferasirox 20 mg/kg/day* 
(initial dose); dose adjustments 
in steps of 5–10 mg/kg/day 
based on serum ferritin and 
safety markers
•   After 1 year: 57% of patients had treatment 
success (P = 0.016)†  
Mean reduction in LiC: 3.4 mg Fe/g dw 
(P  0.001)  
Proportion of patients with LiC  7 mg Fe/g 
dw had risen from 9.9% at baseline to 26.2%  
in patients whose therapeutic goal was 
reduction, significant decrease in serum 
ferritin (–517 mg/mL; P  0.001)
ePiC: Open-label, 
1-year26
Pediatric (2 years) and adult 
patients with β-thalassemia, MDS, 
DBA, SCD,   AA and other rare 
anemias, n = 1744
Deferasirox 10–30 mg/kg/day 
(initial dose dependent on 
blood transfusion frequency); 
dose adjustments in steps of 
5–10 every 3 months based 
on serum ferritin and safety 
markers
•   At end of study: Proportion of patients 
with LiC  7 mg Fe/g dw had risen to 
44.4%. Further decreases in LiC and serum 
ferritin observed
•    Significant reduction in serum ferritin 
from baseline in overall population 
(–264 ng/mL; P  0.0001), reflective of 
dosage adjustments and ongoing iron  
intake
•    Significant reduction in serum ferritin in 
each disease cohort
Abbreviations: AA, aplastic anemia; DBA, Diamond-Blackfan anemia; DFO, deferoxamine; dw, dry weight; LiC, liver iron concentration; MDS, myelodysplastic syndromes; 
SCD, sickle cell disease.Therapeutics and Clinical Risk Management 2009:5 860
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937 patients with β-thalassemia major were enrolled and 
where a significant decrease in serum ferritin was observed 
after 1 year of deferasirox treatment (Table 2).30 In the 
ESCALATOR study, the proportion of β-thalassemia major 
patients with a LIC of 7 mg Fe/g dry weight (dw) increased 
from 9.9% at baseline, to 26.2% at 1 year and 44.4% at the 
end of study (median of 2.7 years).25 With appropriate dose 
adjustments, deferasirox continues to be effective over the 
long term in patients with β-thalassemia major, a finding 
that is supported by data from the extension studies over a 
median treatment period of 4.5 years (Figure 2).28
Cardiac failure related to myocardial iron overload is the 
leading cause of death in regularly transfused patients with 
β-thalassemia major.4,36 Evidence for the ability of deferasirox 
to remove cardiac iron in patients with β-thalassemia major 
has been demonstrated in a number of studies.37–41 The 
largest of these was a substudy of EPIC, where deferasirox 
significantly improved myocardial T2* in patients with mild, 
moderate and severe myocardial siderosis (11.2 ms at baseline 
to 12.9 ms at 12 months; P  0.0001) (Figure 4a).41 Left 
ventricular ejection fraction (LVEF) is a useful surrogate 
marker of cardiac function and is often used when evaluating 
the cardiac efficacy of an iron chelator. It was evaluated in 
the EPIC and ESCALATOR trials, which enrolled patients 
with baseline LVEF within the reference range for healthy 
adults (ie, 56%). LVEF, as measured by echocardiogram 
or cardiovascular magnetic resonance, was maintained at 
approximately 67% in the EPIC substudy,41 and improved 
significantly from 65.1% to 66.8% (P = 0.0002) in the 1-year 
core ESCALATOR study.24 As well as removing iron from 
the heart, deferasirox may also prevent the accumulation of 
cardiac iron in iron-overloaded patients with normal cardiac 
iron levels (Figure 4b).42 This ability may potentially help in 
preventing future cardiac failure associated with myocardial 
siderosis in patients with β-thalassemia major.
β-thalassemia intermedia
Although patients with β-thalassemia intermedia are rarely 
transfused they are still at risk for developing iron overload 
due to increased intestinal iron absorption secondary to 
chronic anemia. Few studies with chelation therapy have 
been conducted in this population to date. However, data 
are emerging from small numbers of patients demonstrating 
that deferasirox can significantly decrease mean serum 
ferritin levels over 1 year of treatment (1356 to 914 ng/mL, 
P  0.05;43 2030 to 1165 ng/mL, P = 0.02,44 at doses of 10 to 
20 mg/kg/day, respectively). A large prospective study is 
underway to fully evaluate the use of deferasirox in patients 
with thalassemia intermedia.
Myelodysplastic syndromes
Several studies have demonstrated the efficacy of deferasirox 
in maintaining or reducing body iron burden in patients 
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with MDS.22,31,45–48 As in the β-thalassemia population, 
deferasirox has dose-dependent efficacy in patients with 
MDS.22 The largest cohort of MDS patients (n = 341) ever 
assessed with iron chelation therapy were enrolled in the 
EPIC study; with appropriate dose adjustments, significant 
reductions in serum ferritin were noted after 1 year of 
deferasirox treatment (Table 2).26,31 Another large study in 
176 heavily iron-overloaded MDS patients also showed 
decreases in serum ferritin.46 Preliminary data suggest that 
in addition to decreases in serum ferritin, improvements 
in hematological parameters can occur with deferasirox 
treatment in patients with MDS.49 Serum ferritin decreases 
during deferasirox treatment in patients with MDS have 
been shown to be associated with significant improvements 
in alanine aminotransferase (ALT), which is an indicator of 
hepatocellular injury.47,50 This is of importance given that 
liver dysfunction is a common complication in MDS;51,52 
prospective studies are warranted to further investigate this 
observation. MDS patients who are most likely to benefit 
from receiving chelation therapy are transfusion-dependent 
patients with lower-risk MDS (ie, Low or Int-1 International 
Prognostic Scoring System) and life expectancy 1 year, who 
have serum ferritin levels of 1000 ng/mL.53,54
Sickle cell disease
Deferasirox has also demonstrated dose-dependent efficacy 
in the SCD population.23 In one Phase II study in adult 
and pediatric patients, LIC was significantly reduced from 
baseline after 1 year of deferasirox treatment (P  0.05).23 
Serum ferritin levels were also decreased, although there 
was substantial intrapatient variability. Deferasirox doses of 
10 to 30 mg/kg/day were shown to have similar efficacy to 
DFO. Of 195 patients enrolled in this 1-year study, 132 entered 
the ongoing extension phase. To date, these patients have 
received deferasirox for a median treatment period of 
3.1 years and have shown continued reduction in serum 
ferritin levels (–651 ng/mL from baseline; P = 0.0533).55 
Further evidence for the efficacy of deferasirox in SCD 
is emerging from smaller studies that have demonstrated 
substantial reductions in serum ferritin and liver iron levels 
over 1 year.56,57
Aplastic anemia, Diamond-Blackfan anemia,  
and other rare anemias
Patients with AA, DBA and other types of rare anemia often 
require blood transfusions as supportive therapy; however, 
the efficacy of chelation therapy has rarely been evaluated 
in these populations. A 1-year prospective Phase II trial with 
deferasirox included 30 patients with DBA and 22 patients 
with other rare anemias (including AA, α-thalassemia and 
sideroblastic anemia).22 Significant, dose-dependent effects 
on LIC and serum ferritin were observed in both groups 
over the 1-year treatment period.22,58,59 Patients with AA 
(n = 116), DBA (n = 14) and rare anemias (n = 43) were also 
enrolled in the EPIC study and significant overall reductions 
in serum ferritin from baseline to 1 year were observed in 
each of the disease groups (Table 2).32–34 As with the overall 
EPIC population, changes in serum ferritin were reflective 
of dose adjustments and iron intake during the study. A simi-
lar observation has been made based on interim data from 
50 patients with AA in Korea, where significant reductions in 
mean LIC (P = 0.01) and serum ferritin (4185 to 2913 ng/mL, 
P  0.01) were noted over the 1-year treatment period.48
Pediatric patients
The deferasirox clinical trial program included patients with 
a wide range of ages. Pediatric patients (aged 2 to 16 years) 
were well represented, comprising approximately 40% of 
all patients enrolled in the five pivotal studies. When used 
at appropriate doses for the degree of iron burden and the 
ongoing transfusional iron intake, deferasirox provides dose-
dependent efficacy in pediatric patients for up to 5 years of 
treatment;29,60 these effects are similar to those observed in 
adult patients.28 Efficacy data have been confirmed by the 
large number of pediatric patients (n = 166) enrolled in 
the ESCALATOR study.24 In this heavily iron-overloaded 
pediatric population, significant decreases in mean LIC 
(–7.9 ± 8.7 mg Fe/g dw; P  0.0001) and median serum 
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ferritin (–1126 ng/mL; P  0.0001) were observed after a 
median of 2.8 years’ treatment.61
effect of deferasirox on labile plasma iron
Excess iron in the blood saturates the iron-binding protein 
transferrin leading to non-transferrin-bound iron (NTBI) 
in the plasma. The cellular uptake of NTBI is uncontrolled, 
which can potentially lead to excessive accumulation of labile 
iron in tissues such as the heart, liver and endocrine system. 
This labile iron may be a key mediator of iron toxicity due to 
its ability to catalyze production of reactive oxygen species.62 
Control of labile plasma iron (LPI) is therefore an impor-
tant aim of chelation therapy. In the ESCALATOR study in 
patients with β-thalassemia, LPI levels were analyzed using 
an assay that measured iron-specific redox cycling capacity 
in the presence of low ascorbate concentrations.63 Redox 
reactions were detected by the oxidation of a fluorogenic 
probe to its fluorescent form, which allowed distinction 
of chelator-bound from chelator-free LPI. Data from this 
study demonstrated that daily trough levels of deferasirox 
are sufficient to maintain suppression of LPI (Figure 5).64 
After 4 weeks of treatment and throughout the remainder 
of the 1-year treatment period, peak LPI levels observed 
just before deferasirox dosing were significantly decreased 
compared with baseline and remained within normal values. 
Similar sustained reductions in LPI with deferasirox have 
been observed in other disease cohorts, including MDS and 
AA.46,65,66 These findings support the concept that once-daily 
deferasirox therapy may decrease unregulated tissue iron 
loading and prevent further end-organ damage across various 
transfusion-dependent anemias.
Safety and tolerability of deferasirox
Deferasirox has a well characterized and manageable safety 
profile in adult and pediatric patients as young as 2 years 
with various transfusion-dependent anemias.20–23 Most 
patients remain on deferasirox therapy and adverse events 
are not a common reason for study discontinuation; eg, only 
74 of 1000 patients enrolled in the core clinical studies 
discontinued treatment with deferasirox due to the occur-
rence of adverse events.16,20–23 The most common drug-related 
adverse events reported during deferasirox treatment include 
transient, mild-to-moderate gastrointestinal disturbances 
(such as nausea, vomiting, abdominal pain and diarrhea) 
and skin rash; these events generally resolved spontaneously. 
For severe skin rash deferasirox should be interrupted until 
the rash has resolved; reintroduction at a lower dose with 
subsequent gradual escalation may then be considered in 
combination with a short period of oral steroid administration. 
Mild, non-progressive increases in serum creatinine, gener-
ally within the upper limit of normal (ULN), were observed 
in approximately one-third of patients in the pivotal 1-year 
clinical trials.16,20–23 Serum creatinine levels spontaneously 
returned to baseline in approximately two-thirds of patients 
who experienced these increases.67 There were no cases of 
moderate-to-severe renal insufficiency or renal failure and no 
patients permanently discontinued treatment due to creatinine 
increases. If there is an increase in serum creatinine beyond 
the age-appropriate ULN, deferasirox should be interrupted 
until levels have returned to the normal range. Treatment may 
then be restarted at a lower dose with gradual escalation. In the 
1-year studies elevations of liver transaminases were reported 
in about 2% of patients; these were not dependent on dose 
and most patients had elevated baseline levels. Elevations 
greater than 10 × ULN, suggestive of hepatitis, were 
uncommon (0.3%).10 Following any unexplained, persistent, 
or progressive increases in serum transaminases, deferasirox 
treatment should be interrupted. Once the cause of the 
transaminase increases has been established or when levels 
have returned to normal, deferasirox may be restarted at a 
lower dose followed by gradual escalation.
The tolerability and safety profile of deferasirox in 
pediatric patients is similar to that observed in adults.29 
As growth retardation and hypogonadism remain significant 
Table 2 Efficacy of deferasirox across various transfusion-dependent anemias: data from the EPIC trial
β-thalassemia major  
(n = 937)30
MDS  
(n = 341)31
AA  
(n = 116)32
Rare anemias  
(n = 43)33
DBA  
(n = 14)34
Baseline, ng/mL* 3157 2730 3254 3161 2289
Change at 1 year, ng/mL* –129 –253 –964 –832 –790
P value 0.0007 0.0019 0.0003 0.0275 0.0121
Deferasirox dose, mg/kg/day** 24.2 ± 5.6 19.2 ± 5.4 17.6 ± 4.8 18.6 ± 5.6 21.0 ± 4.8
*Serum ferritin data are presented as median; **Dose data are presented as mean ± SD.
Abbreviations: AA, aplastic anemia; DBA, Diamond-Blackfan anemia; MDS, myelodysplastic syndromes.Therapeutics and Clinical Risk Management 2009:5 863
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clinical problems in pediatric patients with β-thalassemia, it is 
important to note that growth and sexual development proceed 
normally during deferasirox therapy.24,29 In the ESCALATOR 
study, growth in pediatric patients was assessed based on 
height standard deviation score (h-SDS).68 At baseline, both 
boys and girls were initially smaller than the reference group 
across all ages (2 to 6, 6 to 12 and 12 to 16 years).24 
Over the 1-year study period, the observed growth as 
evaluated by change from baseline in h-SDS showed growth 
improvements (0.5 SDS) in 18.1% of patients, worsen-
ing in growth in 9.4% of patients, and no change from 
baseline in 72.5% of patients. In this population, girls aged 
12 to 16 years showed a notable improvement in growth, 
with 66.7% of this cohort exhibiting a net increase in h-SDS 
(25% percentile or first quartile = –0.06).24
Long-term safety of deferasirox
Safety data with deferasirox has now been reported for up 
to 5 years of treatment (Table 3).28,60,69 Based on 472 patients 
with β-thalassemia who received deferasirox for a median 
of 4.5 years, 50 (10.6%) discontinued due to adverse events. 
The types of drug-related adverse events reported in the 
extension studies were similar to those reported in the initial 
1-year treatment period, and the annual frequency generally 
decreased from year to year, ranging from 0% to 2.3% in 
years 2 to 5.28 In addition, there were no progressive increases 
in serum creatinine over longer-term deferasirox treatment.28 
The long-term safety profile of deferasirox in diseases other 
than β-thalassemia is also available. Deferasirox has a well 
characterized and manageable safety profile in SCD patients 
for up to 3.5 years of treatment and no progressive increases 
in serum creatinine were observed, demonstrating a favorable 
renal safety profile in these patients who are at risk of pro-
gressive renal disease.69 In MDS patients the most common 
adverse events are gastrointestinal disturbances and skin rash, 
similar to that observed with β-thalassemia patients.31
Drug interactions and post-marketing 
surveillance
Deferasirox inhibits CYP3A4 and CYP2C8 in vitro, therefore 
caution should be used when administering deferasirox with 
drugs metabolized by these enzymes. Deferasirox also inhibits 
CYP1A2, CYP2A6, CYP2D6, and CYP2C19, however the 
clinical significance of this is unknown. The concomitant 
use of deferasirox with potent UDP-glucuronosyltransferase 
inducers (eg, rifampicin, phenytoin, phenobarbital, ritonavir) 
may result in a decrease in deferasirox efficacy. The 
concomitant administration of deferasirox with other iron 
chelators, aluminum-containing antacid preparations, 
vitamin C or hydroxyurea has not been formally studied. 
There have been post-marketing reports of cytopenias (both 
spontaneous and from clinical trials) in patients treated 
with deferasirox, although all of these patients had either 
pre-existing hematologic disorders that are commonly 
associated with bone-marrow failure or complications of 
the underlying disease that are associated with cytopenias 
(eg, hypersplenism, sickle cell crisis, administration of 
chemotherapy). The relationship of these episodes to 
treatment with deferasirox is uncertain. As with the standard 
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Table 3 Most common drug-related adverse events during a median 
4.5-year treatment period with deferasirox in 472 patients with 
β-thalassemia28*
Adverse event Frequency, n (%)
Abdominal pain 62 (13.1)
Nausea 55 (11.7)
Diarrhea 40 (8.5)
vomiting 32 (6.8)
Rash 23 (4.9)
*Pooled data from core and extension phases of 4 pivotal studies.Therapeutics and Clinical Risk Management 2009:5 864
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clinical management of such hematological disorders, blood 
counts should be monitored regularly. Post-marketing cases of 
acute renal failure, some with a fatal outcome, have also been 
reported. Most of the fatalities occurred in patients with severe 
complications related to the underlying disease (eg, patients 
with multiple co-morbidities who were in advanced stages of 
disease). It is therefore recommended that particular attention 
is given to monitoring serum creatinine levels in patients who 
have preexisting renal conditions, are elderly, have co-morbid 
conditions that may affect renal function, or are receiving 
medicinal products that depress renal function. There have 
also been post-marketing reports of hepatic failure, some with 
a fatal outcome, in patients treated with deferasirox. Most 
of these events occurred in patients with significant comor-
bidities, including liver cirrhosis and multi-organ failure. 
In addition, upper gastrointestinal ulceration and hemorrhage 
have been reported in some patients, including children and 
adolescents, receiving deferasirox. Physicians and patients 
should remain alert for signs and symptoms of these events 
and promptly initiate additional evaluation and treatment if a 
serious gastrointestinal adverse event is suspected.
Safety at low iron burden and high 
deferasirox doses
Maintaining serum ferritin levels below 1000 ng/mL is 
known to be associated with a reduced risk of iron-overload-
related complications, such as heart failure, in patients with 
thalassemia.5 However, as the use of DFO has been associated 
with increased toxicity at low serum ferritin levels, it is of 
interest to assess the adverse event profile of patients enrolled 
in the deferasirox studies who achieved serum ferritin levels 
of 1000 ng/mL.5,70,71 An analysis of 174 patients demon-
strated a similar safety profile to that observed in patients 
who did not achieve serum ferritin levels of 1000 ng/mL 
(n = 300).72 For example, the frequency of drug-related 
adverse events such as nausea (14.9% vs 12.7%), vomiting 
(8.0% vs 8.3%) and skin rash (5.2% vs 5.3%), were compa-
rable. In addition, similar proportions of patients experienced 
increases in serum creatinine 33% above baseline and 
ULN (14.9% vs 12.0%) and increases in ALT  10 × ULN 
(6.9% vs 6.7%). These data suggest that when appropriately 
dosed, serum ferritin can be maintained at levels lower than 
1000 ng/mL during deferasirox treatment without increases 
in the frequency or type of adverse event reported.73
Data from patients who have received deferasirox doses 
of 30 mg/kg/day demonstrate that the safety profile is 
consistent with that observed at doses of 30 mg/kg/day.35 
The most common drug-related adverse events were gastro-
intestinal events such as vomiting (n = 7, 3.1%), abdominal 
pain and nausea (n = 4, 1.8% for both).35
Health economics of deferasirox
It is well established that compliance is a key factor 
determining outcome of iron chelation therapy,3,74 and 
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the route of administration has an impact on compliance. 
Due to the need for 8- to 12-hour infusions, 5 to 7 times per 
week, compliance with DFO is suboptimal, ranging from 
59% to 78%.6 Poor compliance with treatment can lead to 
serious morbidities and have a significant impact on cost, for 
example complications of iron overload such as heart disease 
or diabetes may increase annual costs by US$40,000.75 As 
deferasirox is a once-daily oral treatment, improvements 
in compliance compared with DFO may lead to improved 
patient outcomes and lower treatment costs. These have been 
evaluated in a number of analyses.
Cost effectiveness of deferasirox
Two separate studies have compared the cost-effectiveness 
of DFO and deferasirox.76,77 In a US model, treatment with 
deferasirox resulted in an additional 4.5 quality adjusted life 
years (QALYs) per patient at an additional lifetime cost of 
US$126,018 per patient, translating into a cost-effectiveness 
ratio of US$28,255 per QALY gained.76 Deferasirox was also 
associated with lower net costs and higher QALYs than DFO 
in a UK-based model.77 In this analysis drug dose and cost was 
relayed to patient weight; for patients with a mean weight of 
62 kg the incremental cost per QALY gained was £7775.77
effect of deferasirox on patient-reported 
outcomes
A  number  of  deferasirox  studies  have  evaluated 
patient-reported satisfaction, convenience and treatment 
preference, which may provide surrogate measures for 
treatment compliance, in patients with β-thalassemia, 
SCD and MDS.78–81 In one study, 97% of patients with 
β-thalassemia who switched from DFO to deferasirox 
reported that they preferred deferasirox to DFO, primarily 
due to convenience (37%), no injection-site soreness (25%) 
and less daily disruption (23%).78 Most patients were 
more satisfied with deferasirox therapy and found it to be 
more convenient than DFO (Figure 6).78 Similarly, another 
study found that 91% of 252 patients with β-thalassemia 
were ‘satisfied/very satisfied’ with treatment after 1 year 
compared with 23% at baseline (all patients had received 
DFO and/or deferiprone prior to initiation of deferasirox).80 
Time lost for normal activities due to chelation therapy 
was substantially reduced with deferasirox treatment com-
pared with prior treatments (from 28.8 hours/month at 
baseline to 3.0 hours/month after 1 year).80 Similar results 
have been observed in patients with SCD.81 Improvements 
in health-related quality of life, based on SF-36 domain 
scores (eg, physical functioning and general health), were 
observed during 1 year of deferasirox treatment in patients 
with β-thalassemia (n = 274), MDS (n = 168) and SCD 
(n = 50) who were enrolled in the EPIC study.82
Conclusions and place in therapy
This article demonstrates the efficacy and safety profile of the 
oral iron chelator deferasirox, which has specific advantages 
over the other available chelators due to its formulation and 
route of administration. The large clinical development pro-
gram including patients with various underlying anemias has 
demonstrated the ability of deferasirox to remove iron from 
the liver and heart. The efficacy of deferasirox is dependent 
on appropriate dosing according to current iron burden, 
ongoing transfusional iron intake and safety markers,27,30 and 
regular monitoring of these parameters is necessary to ensure 
dose adjustments are made in a timely manner.10 Recent data 
from a substudy of EPIC have confirmed the findings of 
previous smaller studies demonstrating that deferasirox can 
remove cardiac iron and maintain cardiac function based on 
LVEF.39,41,42 Data from this substudy also show that deferasirox 
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can prevent the accumulation of cardiac iron, highlighting the 
importance of early intervention to aid in the prevention of 
future cardiac events resulting from myocardial siderosis.83–85 
Data from several studies of up to 5 years’ duration provide 
support for the long-term efficacy of deferasirox in main-
taining or reducing overall iron burden across a range of 
anemias.28,55 Deferasirox is well tolerated with a manageable 
safety profile over long-term treatment in both pediatric and 
adult patients. The frequency of treatment-related adverse 
events generally decreases over time; the most common 
adverse events reported are mild-to-moderate gastrointestinal 
disorders and skin rash.28,29,35 The safety profile is similar at 
doses above and below 30 mg/kg/day and at serum ferritin 
levels above and below 1000 ng/mL.72 Improved satisfaction 
with, and convenience of, deferasirox compared with DFO 
has also been shown,78–81 which may translate into improved 
compliance and subsequent cost savings. In conclusion, 
once-daily oral therapy with deferasirox provides a significant 
development in the treatment of iron overload in patients with 
transfusion-dependent anemias.
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